This audit is for medical oncology trainees deciding whether Licence Medical belongs in their SCE revision stack, and for which job. In short: Licence Medical publishes a dedicated SCE Medical Oncology question bank with detailed explanations and PDF revision notes — a genuine point in its favour, given that some generalist banks skip this specialty entirely — but its live question count, price, access period and any adaptive features are not published on its accessible product pages, so verify them directly before buying. The principal limitation of any single standard bank, this one included, is that it cannot measure whether your knowledge transfers to unseen questions or confirm it is anchored to UK practice.
Current-state box: what Licence Medical states
Last checked 21 July 2026. Licence Medical (license-medical.com) markets UK MRCP and Specialty Certificate Examination revision, and its catalogue lists a Medical Oncology SCE question bank alongside other specialties, emphasising detailed explanations and PDF revision notes. It does not clearly publish a live question count, price, access period, free trial or any AI/adaptive feature on the pages reviewed, directing enquiries to the vendor by email. We therefore state no number: verify the current count, price and access terms on the product page or with the vendor before purchase. Context that matters for this specialty: not every bank covers Medical Oncology — BMJ OnExamination did not publish an SCE Medical Oncology bank as of 21 July 2026 — so a provider that does cover it is worth considering, but so is the more transparent specialist StudyPRN, which lists a vendor-reported Medical Oncology bank of around 498 questions across 22 categories with a three-hour mock at £89 for three months, as of 21 July 2026 and subject to change.
Exam anchor: the SCE format and blueprint
The SCE in Medical Oncology is delivered by the Federation of Royal Colleges of Physicians as two papers of 100 best-of-five questions — 200 in total — each paper three hours, on one day, at a Surpass computer-based test centre, one mark per correct answer, no negative marking. The blueprint samples the whole JRCPTB curriculum: site-specific tumours (breast; lung and thoracic; gastrointestinal; genitourinary; gynaecological; head and neck; central nervous system; skin; sarcoma; lymphoma; carcinoma of unknown primary) and non-site-specific themes (acute oncology and emergencies; systemic anti-cancer therapy and immunotherapy toxicity; radiotherapy principles; supportive and palliative care; cancer genetics; screening and prevention; trials, statistics and governance). The Federation's format and blueprint are authoritative; a vendor's "covers the blueprint" claim is a statement to be verified against your own audit.
Record the count by domain, not the headline
Because Licence Medical does not publish a headline count, tally coverage yourself as you work through the bank in blueprint order, recording how many questions you actually meet per domain. Oncology banks commonly cluster around the common cancers — breast, lung, colorectal — and thin out in sarcoma, neuroendocrine tumours, germ-cell tumours and carcinoma of unknown primary, and in the cross-cutting themes of trials and governance. A per-domain tally turns an unverifiable total into an evidence-based coverage map and shows you exactly where the bank will and will not carry you.
Sample the question style
Audit a stratified sample for cognitive demand. Check recall versus application: does an item ask you to recognise a fact, or to move from a biomarker result or a staging work-up to the correct systemic-therapy decision? Assess stem length and realism, distractor plausibility, and whether genuine image and data interpretation is present — cross-sectional imaging for staging and response, described histology, tumour-marker and biochemistry trends, and dosing calculations such as the Calvert formula for carboplatin. Toxicity-management and management-sequencing items are strong markers of exam-grade difficulty in oncology; note whether the bank includes them or leans on simpler single-fact recall.
Jurisdiction and recency
Check a stratified sample against current UK guidance and record the review date. Jurisdiction is especially important in oncology, because a regimen standard in an international guideline may not be commissioned in the UK. Confirm explanations reflect NICE technology appraisals, the Cancer Drugs Fund position, UK acute-oncology guidance and the SmPC via the electronic medicines compendium, and pay close attention to the fastest-moving areas — immunotherapy indications and toxicity thresholds, biomarker-directed therapy and antibody-drug conjugates — where a static explanation ages quickly. If a sample shows non-UK or dated content, weight the bank toward early learning and calibrate your final decisions on the Federation's official sample.
Format gap: what a standard bank cannot do
State it plainly: a standard bank, however detailed, under-trains four things this exam rewards. It cannot fully rehearse staging as an applied skill, only test recognition of staging facts. It cannot guarantee your biomarker-to-therapy reasoning is current, because targeted-therapy indications shift faster than explanations are rewritten. It cannot keep pace with rapidly changing therapies by itself. And it cannot, alone, confirm your toxicity management transfers to unseen items under time pressure. These are the limits of the format, not a specific fault of Licence Medical, and they are why an unseen measurement layer and official-sample calibration belong alongside any bank.
Duplication and contamination
Assess repeated concepts and near-duplicate stems. In a specialty where the common cancers dominate, banks can over-sample them and recycle similar stems, so rising accuracy may reflect recognition of familiar items rather than competence. The tell is accuracy climbing while your sense of difficulty falls — contamination, and the cue to stop re-running the bank and measure on genuinely unseen questions instead. The mechanism by which this inflates your headline number is set out in our note on why a Q-bank percentage is not your exam score.
Best-fit matrix
On the evidence, Licence Medical is best positioned as a foundation-building and first-pass coverage bank for candidates who value explanation-led learning and PDF notes, once you have verified its count and price and confirmed its per-domain depth in the rarer tumours. It can act as a second bank where duplication against your primary source is low. It is less suited alone to the final-simulation and retake roles, which need clean unseen mixed papers, UK-jurisdiction re-anchoring and official-sample calibration. Choose the tool for the phase rather than expecting one bank to do every job.
Worked example: a seven-day plan around clinical work
A realistic week for a trainee revising around oncology service, using Licence Medical for one defined job — explanation-led first-pass coverage — and iatroX for unseen transfer measurement. No proprietary-algorithm claims; the mechanism is ordinary spaced, mixed retrieval.
- Monday: Timed 30-question Licence Medical block on a weak site (say, genitourinary); read every explanation; code errors by domain, process, format and jurisdiction. 50 minutes.
- Tuesday: Spaced retrieval of Monday's misses plus a Calvert-formula and creatinine-clearance drill. 20 minutes.
- Wednesday: New Licence Medical block on a cross-cutting theme (systemic-therapy toxicity); log high-confidence and jurisdiction errors separately. 45 minutes.
- Thursday: Fresh, timed, unseen mixed block in iatroX; record first-attempt accuracy to measure transfer. 30 minutes.
- Friday: Review error codes; read the relevant NICE appraisal for any recency-flagged therapy. 30 minutes.
- Saturday: Longer 50-question timed mixed block for stamina. 75 minutes.
- Sunday: Update the coverage table; plan next week. Rest otherwise.
Every four to six weeks, replace one session with a Federation official-sample calibration under full exam conditions.
Decision checklist: continue, supplement, switch or stop
Use measurable gaps, not novelty or sunk cost. Continue with Licence Medical while your per-domain tally shows real gaps it can fill and its explanations teach you. Supplement with a second, unseen bank such as iatroX once recognition is high but transfer lags, and add a UK-guidance re-anchor if jurisdiction errors appear. Switch your primary bank only for measurable faults — dated or non-UK content, weak distractors, heavy duplication or thin coverage of the rarer tumours. Stop adding new questions when your unseen mixed score is comfortably above the standard, your jurisdiction errors have resolved, your official-sample calibration is clean, and your remaining mistakes are careless.
Three mistakes this audit is designed to stop
The first mistake is buying on an unverifiable claim: with Licence Medical's count, price and access terms not published on its accessible pages, "covers the blueprint" stays a marketing line until your own per-domain tally proves it — and in oncology that means checking depth in the rarer tumours, not just breast and lung. The second mistake is letting a bank that over-samples the common cancers convince you that rising accuracy is competence, when it is recognition of familiar stems. The third mistake is treating a UK exam as though international oncology answers will pass; a regimen standard in a trial or a European guideline may not be commissioned in the NHS, so a bank's currency and jurisdiction matter as much as its size. Audit all three before you rely on it.
Bottom line
Licence Medical covering Medical Oncology at all is a point in its favour, given that some generalist banks skip the specialty, and it is a reasonable explanation-led first-pass bank once you verify its figures and confirm its depth in the rarer tumours. It is not a calibration or measurement tool on its own. Cover with it, re-anchor decisions on UK guidance, calibrate on the Federation's official sample, and measure transfer on an unseen bank such as iatroX.
Frequently asked questions
Is Licence Medical enough for SCE Medical Oncology on its own? It can carry a large share of coverage if its per-domain distribution matches the blueprint — including the rarer tumours — and its content is current UK practice, but no single standard bank is enough alone, because it cannot honestly measure transfer to unseen questions or guarantee UK-jurisdiction accuracy. Pair it with the Federation's official sample for calibration and a second, unseen bank for measurement. Since the count is unpublished, confirm the bank is deep enough in your weak sites before relying on it as your only source.
Which SCE Medical Oncology component does Licence Medical not reproduce well? Like any static bank, it under-reproduces applied staging, current biomarker-directed decisions, timed toxicity management and the mixed, blueprint-blind sequencing of the real paper, and it cannot guarantee guideline currency. Its strength is explanation-led learning; the components it cannot fully rehearse are best covered by timed mixed simulation, UK-guidance re-anchoring and official-sample calibration.
How many Licence Medical questions should I complete per day for SCE Medical Oncology? With the total unpublished, set a process target: a sustainable timed block of 30 to 40 questions per study day with full explanation review and four-way error-coding (domain, process, format, jurisdiction), adjusted to your rota. Analysed depth beats skimmed volume. Track your per-domain tally so you know when a site is exhausted and it is time to move on or measure elsewhere.
When should I stop using Licence Medical and move to mixed mocks? Move toward full-length mixed mocks in the final three to four weeks, once your site-level accuracy is adequate and your outstanding needs are pacing, stamina and UK best-answer discipline. Keep Licence Medical only for patching specific gaps the mocks reveal; let blended, timed papers and official-sample calibration take over as the exam nears.
How should I combine Licence Medical with iatroX without duplicating practice? Assign distinct roles: Licence Medical as the explanation-led oncology coverage bank, iatroX as the unseen cross-specialty UK measurement layer. Because iatroX is a broad UK MRCP-level bank rather than a specialty oncology SCE product, its items will not duplicate Licence Medical's — which is precisely what makes it a clean second measurement rather than more of the same, following the two-Q-bank rule. One bank to learn and cover; the other to measure whether it transferred.
Editorial notes and references
Written by Dr Kolawole Tytler, NHS GP and founder of iatroX. Last checked 21 July 2026. Licence Medical publishes an SCE Medical Oncology bank, but its live question count, price, access period and any adaptive features are not stated on its accessible product pages as of 21 July 2026; we have not invented figures — verify current details on the product page or with the vendor. Coverage note: BMJ OnExamination did not publish an SCE Medical Oncology bank as of 21 July 2026, and the ESMO Examination is a separate European assessment; calibrate against the Federation's official sample. StudyPRN comparison figures are vendor-reported on 21 July 2026 and change without notice. Disclosure: iatroX operates a UK question bank and competes with Licence Medical; its role here is confined to unseen measurement and cross-specialty knowledge. Corrections via the feedback route on iatrox.com.
References: Licence Medical — Medical Oncology SCE; Federation of Royal Colleges of Physicians — SCE in Medical Oncology; iatroX — why a Q-bank percentage is not your exam score and the SCE Medical Oncology content-gap checklist.